Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Merck & Co., Inc.
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
CDC’s ACIP Unanimously Votes to Provisionally Recommend Use of Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) as an Option for Pneumococcal Vaccination in Infants and Children
June 22, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
U.S. FDA Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Infants and Children
June 22, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Results From Phase 3 PROpel Trial of LYNPARZA® (olaparib) Plus Abiraterone in First-Line Metastatic Castration-Resistant Prostate Cancer Published in NEJM Evidence
June 21, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces that Chirfi Guindo will Lead Marketing for Merck Human Health
June 21, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Presents Positive Results from Phase 1/2 Study Evaluating V116, the Company’s Investigational Pneumococcal Conjugate Vaccine for Adults
June 21, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Stage IB (≥4 centimeters)-IIIA Non-Small Cell Lung Cancer Following Complete Surgical Resection
June 13, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Participate in the 2022 Goldman Sachs 43rd Annual Global Healthcare Conference
June 08, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck and Ridgeback Announce New Data For Investigational LAGEVRIO™ (molnupiravir) From Phase 3 MOVe-OUT Study
June 07, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Hold Investor Event to Highlight Oncology Portfolio and Pipeline
June 07, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Adjuvant Treatment With Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Statistically Significant & Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients With Resected Stage IIB or IIC Melanoma in Phase 3 KEYNOTE-716 Trial
June 05, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Third-Quarter 2022 Dividend
May 24, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Adjuvant Monotherapy After Surgery for Locally Advanced or Early-Stage Triple-Negative Breast Cancer at High Risk of Recurrence
May 24, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Adolescent (≥12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection
May 20, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck To Present Data at 2022 ASCO Annual Meeting Highlighting Promising Pipeline Medicines and Significant Progress in Treating Earlier Stages of Certain Cancers With KEYTRUDA® (pembrolizumab)
May 10, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Participate in Bank of America Securities 2022 Healthcare Conference
May 04, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients With Microsatellite Instability-High (MSI-H) or Deficient Mismatch Repair (dMMR) Tumors in Five Different Types of Cancer
April 29, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS ≥1)
April 29, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces First-Quarter 2022 Financial Results
April 28, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Adjuvant Monotherapy After Surgery for Locally Advanced, or High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
April 25, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces That Joseph Romanelli Will Lead Merck Human Health International, Effective August 1, 2022
April 20, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces U.S. FDA has Granted Breakthrough Therapy Designation for V116, the Company’s Investigational 21-Valent Pneumococcal Conjugate Vaccine, for the Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults
April 14, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Hold First-Quarter 2022 Sales and Earnings Conference Call April 28
April 08, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Investor Event Today Will Highlight Broad and Growing Cardiovascular Portfolio and Pipeline in Areas of Unmet Patient Need
April 05, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Expansion of Elkton, Virginia Manufacturing Facility to Further Increase Merck’s HPV Vaccine Supply and Support Broader and Equitable Access
April 04, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Provides Update on FDA Review of Supplemental Biologics License Application for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Use in Infants and Children
April 01, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck and Ridgeback to Present Data Demonstrating That Treatment With LAGEVRIO™ (molnupiravir) Was Associated With More Rapid Elimination of Infectious SARS-CoV-2 Than Placebo
April 01, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) for Patients With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors in Five Different Types of Cancer
March 25, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, as Treatment for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS ≥1)
March 25, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Retirement of Dr. Roy D. Baynes; Dr. Eliav Barr Appointed Head of Global Clinical Development and Chief Medical Officer
March 23, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Systematic Review and Meta-Analysis of Real-World Observational Studies Provide Additional Evidence of Effectiveness of PREVYMIS™ in Preventing Cytomegalovirus Infection and Disease in Adults Undergoing Allogeneic HCT
March 22, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.